Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;12(3):325-329.
doi: 10.4103/tjo.tjo_30_22. eCollection 2022 Jul-Sep.

Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy

Modupe O Adetunji  1 , Brian J Nguyen  1 , Brendan McGeehan  1 , Madhura A Tamhankar  1 , César A Briceño  1
Affiliations

Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy

Modupe O Adetunji et al. Taiwan J Ophthalmol. .

Abstract

Purpose: To examine changes in intraocular pressure (IOP) in patients with thyroid eye disease (TED) following teprotumumab.

Materials and methods: A retrospective review of 17 patients with TED who received teprotumumab between January 2020 and September 2021 was conducted. IOP, extent of proptosis, and clinical activity score were reviewed at baseline and at 6 weeks, 12 weeks, and 24 weeks for patients undergoing teprotumumab treatment. The primary outcome measure was change in IOP, while secondary outcome measures included changes in proptosis and clinical activity score.

Results: Of the 17 patients (34 eyes) with TED who were treated with teprotumumab, the mean age was 50.5 years, and 15 (88%) were female. The mean baseline IOP was 20 mm Hg (range 13-28), and the mean baseline clinical activity score was 3.8 (range 0-6). Of the 34 eyes examined at baseline, examinations were repeated in 16 at 6 weeks, 26 at 12 weeks, and 8 at 24 weeks. At week 6 of treatment, mean IOP decreased by 4.9 mm Hg (P < 0.0001). At week 12 of treatment, mean IOP decreased by 4.6 mm Hg (P < 0.0001). Mean IOP was decreased at last record of follow-up by 4.9 mm Hg (P < 0.0001).

Conclusion: Among patients with TED, teprotumumab treatment was associated with a reduction in IOP.

Keywords: Intraocular pressure; orbital congestion; proptosis; teprotumumab; thyroid eye disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interests of this paper.

Figures

Figure 1
Figure 1
Distribution of intraocular pressure over time during teprotumumab treatment in patients with thyroid eye disease. Error bars represent mean ± standard deviation. P values shown were calculated by modeling the effect of time on IOP using generalized estimating equations. IOP = Intraocular pressure
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves' orbitopathy. Clin Endocrinol (Oxf) 2005;63:395–402. - PubMed
    1. Smith TJ, Hegedüs L. Graves' Disease. N Engl J Med. 2016;375:1552–65. - PubMed
    1. Behrouzi Z, Rabei HM, Azizi F, Daftarian N, Mehrabi Y, Ardeshiri M, et al. Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. J Glaucoma. 2007;16:358–62. - PubMed
    1. Cockerham KP, Pal C, Jani B, Wolter A, Kennerdell JS. The prevalence and implications of ocular hypertension and glaucoma in thyroid-associated orbitopathy. Ophthalmology. 1997;104:914–7. - PubMed
    1. Ohtsuka K, Nakamura Y. Open-angle glaucoma associated with Graves disease. Am J Ophthalmol. 2000;129:613–7. - PubMed